Skip to main content
OpenTrials
Completed

NCT Number: NCT02196350

P4 Approach in Diabetes Type 2

The study aims to assess the impact of the P4 approach on established markers of glucose metabolism in type 2 diabetics.

Secondary objectives are examination of the changes in physical characteristics, quality of life and the indices for beta cell function, hepatic insulin resistance and muscle insulin resistance .

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Huisartsenpraktijk Elsbroek, Hillegom, South Holland, Netherlands

Loading trial locations.

About this study

This study will be a proof-of-principle exploratory study. Subjects in the P4 program will receive a personalized diagnosis and treatment. After investigation of the status of the different organs involved in diabetes (liver, muscle, pancreas), subjects in the P4 group are divided into 3 subgroups. Each subgroup receives a personalized lifestyle advice. This lifestyle advice may comprise different interventions, i.e. very low calorie diet, low calorie diet, strength training, endurance training. Dependent on the type of intervention, these interventions will be supervised by a dietitian or physiotherapist.

All subjects will visit a central study center 5 times during the study and 3 times during follow-up. During these visits physical measures will be taken and data will be collected by the general practitioner assistant.

After the three month intervention period the subjects will return to usual care via the general practitioner.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy as assessed by the
  • health and lifestyle questionnaire, (P9607 F02; in Dutch)
  • physical examination
  • results of the pre-study laboratory tests
  • Age 30-80 years
  • Stable BMI 25-35 kg/m2
  • Diagnosis diabetes type 2 based upon:

Fasting glucose >6.9 mmol/l on two different days or one measurement of non-fasting glucose >11.0 mmol/l in combination with symptoms of hyperglycemia

  • Duration of diabetes maximally 1 year
  • Informed consent signed;
  • Willing to comply with the study procedures during the study;
  • Appropriate veins for blood sampling/ cannula insertion according to the general practitioner assistant (GPA);
  • Voluntary participation
  • Physically able to perform training activities
  • Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years.

Exclusion criteria

  • Use of insulin, corticosteroids (systemic), or beta-blockers in past month
  • Diabetes occurring after several attacks of pancreatitis known as pancreatic diabetes
  • Slow onset type 1 diabetes
  • Use of oral diabetes medication in past year
  • (Having a history of a) medical condition that might significantly affect the study outcome as judged by the medical investigator and health and life style questionnaire. This includes diabetes type 1, gastrointestinal dysfunction, diseases related to inflammation or allergy, or a psychiatric disorder.
  • Hypertension: systolic blood pressure >160 mmHg, diastolic blood pressure >90 mmHg
  • Kidney problems based upon proteinuria and creatinine >150 mmol/l
  • Insufficient beta cell function based on Disposition index < 1.5 as determined during the OGTT in study on day 01*
  • Physical activity higher than according to the Diabetes guidelines (moderate intensity one hour a day, seven days a week (overweight adults))
  • Alcohol consumption > 21 (women) - 28 (men) units/week
  • Reported unexplained weight loss or gain of > 2 kg in the month prior to the pre-study screening
  • Recent blood donation (<1 month prior to the start of the study)
  • Not willing to give up blood donation during the study
  • Personnel of TNO and their partner
  • Not having a general practitioner
  • Not willing to accept information-transfer concerning participation in the study, or information regarding his health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.

Treatment and study plan

Intervention A: Diet

Behavioral

subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice

Other names: very low calorie diet based on Modifast meal replacers.

Intervention B: Exercise

Behavioral

subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.

Intervention C: Diet and Exercise

Behavioral

subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.

Other names: very low calorie diet based on Modifast meal replacers.

Primary outcomes

  1. Change in HbA1c levels

    Time frame: In-study at week 0 (baseline) and 13 (end of study); follow-up after 6, 12 and 24 months

    Changes in primary outcome measures will be determined by using a mixed model

  2. Change in 2h glucose levels

    Time frame: In-study at week 0 (baseline) and 13;

    2h glucose will be measured after Oral Glucose Tolerance Test (OGTT). Changes in primary outcome measures will be determined by using a mixed model

  3. Change in fasting blood glucose levels

    Time frame: In-study at week 0 (baseline) and 13 (end of study); follow-up after 6, 12 and 24 months

    After 8 hour fasting. Changes in primary outcome measures will be determined by using a mixed model.

  4. percentage of participants that reach normoglycemia

    Time frame: end of study (after 13 weeks)

    normoglycemia is determined by fasting blood glucose level of less than 6.1 mmol/L

Secondary outcomes

  1. body weight

    Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months

    measured by the general practitioner assistant

  2. blood pressure

    Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months

    measured by the general practitioner assistant

  3. waist circumference

    Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months

    measured by general practitioner assistant

  4. body fat percentage

    Time frame: screening; in-study at week 0, 4, 8 and 13; during follow up after 6, 12 and 24 months

    measured by general practitioner assistant

  5. change indices for muscle insulin resistance

    Time frame: screening; in-study at week 0 and 13;

    at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data.

    Blood will be collected at the blood collection centre in Hillegom

  6. health behaviour change

    Time frame: in-study at week 0, 13; during follow-up at 6, 12 and 24 months

    established by comparing baseline values with end of study values for food intake and physical activity as measured by a Lifestyle-questionnaire

  7. change in vitality as assessed with a vitality questionnaire (Vita-16)

    Time frame: in-study at week 0, 13; during follow-up at 6, 12 and 24 months

  8. change in subjective quality of life as assessed with RAND-36 questionnaire

    Time frame: in-study at week 0, 13; during follow-up at 6, 12 and 24 months

  9. change in indices for beta cell function

    Time frame: screening; in-study at week 0 and 13;

    at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data.

    Blood will be collected at the blood collection centre in Hillegom

  10. change in indices for hepatic insulin resistance

    Time frame: screening; in-study at week 0 and 13;

    at week 0 and 13 the indices will be calculated from Oral glucose tolerance test data.

    Blood will be collected at the blood collection centre in Hillegom

Sponsors and collaborators

Lead sponsor

W.J. Pasman

Other

Registry information

Official study title

The Impact of the P4 Approach, Preventive, Predictive, Personalized and Participatory in Newly Diagnosed Type 2 Diabetics in Hillegom

Acronym: P4P-Hillegom

Important dates

Study start
2014
Primary completion
2019
Study completion
2019
First posted
Jul 22, 2014
Registry last updated
Oct 25, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.